Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small-cell lung cancer (NSCLC).
• EGFR-targeted therapies offer critical treatment options for NSCLC patients.
• Acquired resistance to EGFR-targeted agents is an inevitable challenge in NSCLC treatment.

Purpose of the Study:

• To review methods and best practices for tumor sampling and EGFR mutational testing in NSCLC.
• To highlight the importance of convenient tumor biopsy for identifying resistance mechanisms.
• To emphasize the role of rapid and accurate testing in guiding treatment decisions.

Main Methods:

• Discussion of various tumor sampling techniques for NSCLC.
• Review of methodologies for epidermal growth factor receptor (EGFR) mutational testing.
• Consideration of both tissue biopsy and liquid biopsy specimens.

Main Results:

• EGFR mutational testing enables identification of actionable mutations.
• Accurate testing guides the selection of appropriate targeted therapies.
• Understanding resistance mechanisms necessitates reliable biopsy and testing.

Conclusions:

• Convenient tumor biopsy and precise EGFR mutational testing are essential in NSCLC management.
• These methods are critical for identifying resistance mutations and informing subsequent treatment strategies.
• The review provides best practices for optimizing tumor sampling and EGFR testing in clinical settings.